La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Odyssey Health Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Odyssey Health.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Odyssey Health non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:ODYY - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
4/30/2024	N/A	11	-1	-1	N/A
1/31/2024	N/A	11	-1	-1	N/A
10/31/2023	N/A	-4	-1	-1	N/A
7/31/2023	N/A	-6	-1	-1	N/A
4/30/2023	N/A	-7	-2	-2	N/A
1/31/2023	N/A	-9	-3	-3	N/A
10/31/2022	N/A	-9	-2	-2	N/A
7/31/2022	N/A	-8	-3	-3	N/A
4/30/2022	N/A	-9	-4	-4	N/A
1/31/2022	N/A	-19	-4	-4	N/A
10/31/2021	N/A	-18	-4	-4	N/A
7/31/2021	N/A	-17	-3	-3	N/A
4/30/2021	N/A	-15	-3	-3	N/A
1/31/2021	N/A	-4	-1	-1	N/A
10/31/2020	N/A	-4	-1	-1	N/A
7/31/2020	N/A	-4	-1	-1	N/A
4/30/2020	N/A	-26	0	0	N/A
1/31/2020	N/A	-25	0	0	N/A
10/31/2019	N/A	-25	0	0	N/A
7/31/2019	N/A	-23	0	0	N/A
4/30/2019	N/A	0	0	0	N/A
1/31/2019	N/A	0	0	0	N/A
10/31/2018	N/A	0	0	0	N/A
7/31/2018	N/A	0	0	0	N/A
4/30/2018	N/A	0	0	0	N/A
1/31/2018	N/A	0	N/A	0	N/A
10/31/2017	N/A	0	N/A	0	N/A
7/31/2017	N/A	0	N/A	0	N/A
4/30/2017	0	0	N/A	0	N/A
1/31/2017	0	0	N/A	0	N/A
10/31/2016	0	0	N/A	0	N/A
7/31/2016	0	0	N/A	0	N/A
4/30/2016	0	0	N/A	0	N/A
1/31/2016	0	0	N/A	0	N/A
10/31/2015	0	0	N/A	0	N/A
7/31/2015	0	0	N/A	0	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if ODYY's forecast earnings growth is above the savings rate (2.5%).

Guadagni vs Mercato: Insufficient data to determine if ODYY's earnings are forecast to grow faster than the US market

Guadagni ad alta crescita: Insufficient data to determine if ODYY's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if ODYY's revenue is forecast to grow faster than the US market.

Ricavi ad alta crescita: Insufficient data to determine if ODYY's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if ODYY's Return on Equity is forecast to be high in 3 years time

Odyssey Health Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Odyssey Health, Inc. announced delayed 10-Q filing

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS

Odyssey Health, Inc. (OTCPK:ODYY) executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.

Odyssey Health, Inc. Appoints Jeffrey Conroy as Director

Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote

Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development

Odyssey Health, Inc., Annual General Meeting, Jan 12, 2023

Odyssey Health Inc. Announces Expansion of Executive Team

Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Odyssey Health, Inc. Announces the Successful Completion of Safety Measures for Their Phase I Multi-Day Ascending Dosing (Mad) Clinical Trial

Odyssey Health, Inc. Announces Positive Results from its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug

Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug

Odyssey Health, Inc. Names Vice Admiral (r) Timothy Szymanski to the Military Advisory Board

Odyssey Group International Announces Formation of Military Advisory Board

Odyssey Group International, Inc. Continues Enrollment of its First in Kind Human Clinical Trial of its Proprietary Drug Compound Intended to Treat Concussion

Odyssey Group International, Inc. Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Odyssey Group International, Inc. Approves to Start Human Trial to Treat Concussion

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion

Odyssey Group International, Inc. announced delayed 10-Q filing

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion

Odyssey Group International, Inc. Announces the Completion of the Food and Drug Administration (FDA) Required Toxicology Studies Designed to Support Clinical Trials with Prv-002

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Odyssey Group International, Inc. announced a financing transaction

Odyssey Group International, Inc. announced delayed annual 10-K filing

Odyssey Group International, Inc. announced that it expects to receive $10.6 million in funding from The EquiLux Group, LP, Lincoln Park Capital, LLC

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita